<p>香港，2026 年 4 月 30 日 -（ACN Newswire）- 自 4 月以来，复星国际（香港交易所代码：0656）的 A 股上市子公司已发布 2026 年第一季度业绩。市场将本次报告季视为评估复星在风险清除后恢复盈利能力和实现利润的关键窗口。</p>
<p>根据审慎原则，复星在 2025 财年对某些存在减值迹象的房地产项目，以及非核心业务部门的商誉和无形资产进行了一次性非现金减值准备。这一举措旨在更加专注于核心业务和高增长领域。复星国际董事长郭广昌将上述战略决策形容为 “在晴天修屋顶”，引导公司朝着 “更精简、更健康和更可持续的方向” 发展。</p>
<p>根据第一季度业绩，复星医药作为复星健康板块的核心子公司，2026 年第一季度实现营业收入 100.73 亿元人民币，同比增长 6.93%；归属于母公司的净利润达到 8.71 亿元人民币，同比增长 13.87%。剔除非经常性损益后，归属于母公司的净利润同比增长 21.96%。</p>
<p>作为复星幸福板块的核心子公司，豫园在 2026 年第一季度实现营业收入 96.49 亿元人民币，同比增长近 10%；归属于母公司的净利润达到 1.57 亿元人民币，同比增长显著，增幅达到 203%。此外，舍得酒业和海南矿业的净利润分别在 2026 年第一季度达到 2.32 亿元人民币和 2.01 亿元人民币，均录得显著增长。</p>
<p>市场分析表明，子公司的第一季度业绩反映出整体改善的趋势，突显复星在 2025 年风险清除后的明确增长轨迹。复星在制药和医疗、保险和金融以及文化旅游等领域的基本面依然稳固，而消费板块的稳步复苏预计将进一步支撑增长动能。</p>
<p>创新药物展现出强劲的增长动能，释放快速增长的潜力。</p>
<p>“我们始终致力于药物创新。通过不断加强我们的创新管道，我们正在加速创新技术和产品的临床转化和商业化。目前我们有多个重磅候选药物在管道中，” 郭广昌表示。在他 2026 年致股东信中，他多次强调集团对创新药物的战略关注。</p>
<p>进入 2026 年，复星的创新药物商业化正在加速。4 月 28 日，复星医药公布了 2026 年第一季度业绩。在报告期内，4 个创新药物的新药申请（NDA）获得受理，14 个创新药物的临床试验申请（按批准计算）获得国内外监管机构的批准。其中，地诺单抗注射液（HLX14）在加拿大获得批准，贝伐单抗注射液（HLX04）的 NDA 在美国获得受理，福美宁的 NDA、甲氧基乙酰胺盐酸注射液及一个额外适应症的申请获得国家药品监督管理局（NMPA）受理。</p>
<p>总体而言，这些结果延续了 2025 年创新药物的强劲增长动能。结果显示，2025 年复星医药的 7 个创新药物的 16 个适应症在中国和海外市场获得批准上市，同时 6 个创新药物候选药物的市场申请获得受理。创新药物的收入达到 98.93 亿元人民币，同比增长 29.59%，使得总制药业务收入的比例达到 33.16%。截至 2025 年底，近 40 个创新药物的临床试验获得中国、美国和欧洲监管机构的批准，同时多个核心产品进入关键临床阶段，为未来的商业增长奠定了坚实的管道基础。</p>
<p>作为复星创新药物的标杆企业，恒瑞自 2026 年初以来在创新药物研发和商业化方面取得了快速进展。在研发方面，汉斯珠昂和 HLX07 均取得了突破性进展，多个潜在的 “首创药物” 正在加速进入临床验证阶段。在全球商业化方面，恒瑞与 Eisai Co., Ltd.签署了汉斯珠昂在日本的独家商业化和共同开发及生产许可协议，潜在总对价超过 3 亿美元。同时，恒瑞的一家子公司获得了东京地方政府颁发的药品类型 I 市场授权持有者（MAH）许可证，为进一步拓展主要亚洲和全球制药市场奠定了坚实基础。</p>
<p>复星的创新管道已进入频繁批准和加速商业化的阶段。研发投资和市场回报相互强化，形成良性循环，为持续的盈利增长提供了强有力的支持，提升了全球竞争力。</p>
<p>复星各板块子公司发布稳健业绩，巩固 100 亿元人民币的利润目标。</p>
<p>创新药物的增长动能标志着复星业绩的改善。同时，曾因房地产项目减值而受到影响的豫园，成功度过了行业调整期，增强了复星最薄弱的板块。</p>
<p>在 2026 年第一季度，豫园实现归属于母公司股东的净利润为 1.57 亿元人民币，同比增长 203%。尽管第一季度的净利润仍然较为温和，但强劲的增长势头标志着豫园经营基本面的积极转折，后续的盈利恢复预计将进一步展开。</p>
<p>复星消费板块的另一家子公司舍得酒业也成功回归增长轨道。在 2026 年第一季度，其营业收入达到 14.81 亿元人民币，环比增长 106.45%。与此同时，其净利润达到 2.32 亿元人民币，超过了 2025 年全年净利润 2.23 亿元人民币。</p>
<p>值得注意的是，智能制造板块的海南矿业交出了显著的业绩。受益于下游对储能和动力电池需求的上升，海南矿业在 2026 年第一季度实现营业收入为 11.93 亿元人民币，归属于母公司股东的净利润为 2.01 亿元人民币，同比增长 25.13%，环比大幅增长 69%。综合锂资源价值链稳定运营，为第一季度贡献了 9900 万元人民币的归母净利润，成为核心盈利增长驱动力。此外，油气业务实现了稳定的生产和效率提升。在报告期内，归属的油气产量达到 318.65 万桶当量，同比增长 15.78%。</p>
<p>多个板块子公司的利润增长正在加速，增强了市场对复星未来盈利动能确定性的信心。</p>
<p>此前，复星管理团队在 2025 年年度业绩发布会上明确提出了中期财务路线图：旨在逐步恢复利润至 100 亿元人民币水平，目标是集团层面现金回报达到 600 亿元人民币，将集团总债务降至 600 亿元人民币以下，并力争实现 “投资级” 评级。</p>
<p>为了说明其实现 “100 亿元利润” 目标的计划，复星管理团队解释了 “8424” 重组框架。“8” 对应于四家核心子公司——复星医药、豫园、复星保险葡萄牙和复星旅游集团的 80 亿元人民币利润；第一个 “4” 反映来自海南矿业和峰再保险等二级子公司的 40 亿元人民币利润；“2” 代表来自投资导向企业的约 20 亿元人民币利润；最后的 “4” 指的是集团层面成本的上限为 40 亿元人民币，包括融资费用。在这些 “加减法” 之后，集团旨在恢复 100 亿元人民币的利润水平。</p>
<p>复星在各业务板块的第一季度业绩不仅符合市场预期，得益于其 “阳光天修屋顶” 的努力，还增强了恢复 100 亿元利润水平的信心。分析师指出，持续的创新药物商业化、保险业务的快速增长以及文化旅游和消费业务的稳定，使复星能够进一步释放增长动能。建议投资者密切关注全年盈利增长和估值恢复。</p>
<p>在对长期前景充满信心的支持下，复星正在积极回购股份。从 2025 年年度业绩公告的日期 3 月 30 日到 4 月 27 日，复星国际累计回购 2541 万股。根据公司公告，股份回购计划预计将继续进行。</p>
<p>最近，花旗、瑞银、国泰君安和中国证券等国内外领先证券公司发布了研究报告，对复星的前景表示乐观。花旗指出，基于基本面的改善，复星国际预计将在 2026 年交出强劲的业绩。</p>
<p>版权 © 2026 ACN Newswire。保留所有权利。</p>

复星医药

复星国际

<p>复星国际的子公司报告了 2026 年第一季度的稳健业绩，显示出在风险清除后盈利的恢复。复星医药的收入增长了 6.93%，达到 100.73 亿元人民币，净利润增长了 13.87%。豫园的收入增长近 10%，净利润激增 203%。公司强调其对创新药物的关注，获得了多项批准，并拥有强大的产品线。总体来看，这些业绩反映出积极的增长轨迹，进一步巩固了复星年内 100 亿元人民币的利润目标</p>

<p>HONG KONG, Apr 30, 2026 - (ACN Newswire) - Since April, Fosun International (HKEX: 0656)'s A-share listed subsidiaries have released their Q1 2026 results. The market views this reporting season as a key window to gauge Fosun's capacity to restore earnings and deliver profits following risk clearance.</p>
<div class="lb-trans"><p>香港，2026 年 4 月 30 日 -（ACN Newswire）- 自 4 月以来，复星国际（香港交易所代码：0656）的 A 股上市子公司已发布 2026 年第一季度业绩。市场将本次报告季视为评估复星在风险清除后恢复盈利能力和实现利润的关键窗口。</p>
</div><p>In accordance with the principle of prudence, Fosun made one-off non-cash impairment provisions in the 2025 financial year on certain real estate projects with impairment indicators, as well as goodwill and intangible assets of non-core business segments. This move was aimed at sharpening focus on core businesses and high-growth areas. Guo Guangchang, Chairman of Fosun International, described the above strategic decision as 'repairing the roof on a sunny day', steering the Company toward a 'leaner, healthier, and more sustainable direction'.</p>
<div class="lb-trans"><p>根据审慎原则，复星在 2025 财年对某些存在减值迹象的房地产项目，以及非核心业务部门的商誉和无形资产进行了一次性非现金减值准备。这一举措旨在更加专注于核心业务和高增长领域。复星国际董事长郭广昌将上述战略决策形容为 “在晴天修屋顶”，引导公司朝着 “更精简、更健康和更可持续的方向” 发展。</p>
</div><p>According to the Q1 results, Fosun Pharma, a core subsidiary in Fosun's Health segment, achieved operating revenue of RMB10.073 billion in Q1 2026, representing a year-on-year increase of 6.93%, while net profit attributable to shareholders of the parent reached RMB871 million, representing a year-on-year increase of 13.87%. Excluding non-recurring gains and losses, net profit attributable to shareholders of the parent increased by 21.96% year-on-year.</p>
<div class="lb-trans"><p>根据第一季度业绩，复星医药作为复星健康板块的核心子公司，2026 年第一季度实现营业收入 100.73 亿元人民币，同比增长 6.93%；归属于母公司的净利润达到 8.71 亿元人民币，同比增长 13.87%。剔除非经常性损益后，归属于母公司的净利润同比增长 21.96%。</p>
</div><p>Yuyuan, a core subsidiary in Fosun's Happiness segment, achieved operating revenue of RMB9.649 billion in Q1 2026, representing a year-on-year increase of nearly 10%, while net profit attributable to the parent company reached RMB157 million, representing a significant increase of 203% year-on-year. In addition, Shede Spirits and Hainan Mining recorded notable earnings growth, with net profits reaching RMB232 million and RMB201 million, respectively, in Q1 2026.</p>
<div class="lb-trans"><p>作为复星幸福板块的核心子公司，豫园在 2026 年第一季度实现营业收入 96.49 亿元人民币，同比增长近 10%；归属于母公司的净利润达到 1.57 亿元人民币，同比增长显著，增幅达到 203%。此外，舍得酒业和海南矿业的净利润分别在 2026 年第一季度达到 2.32 亿元人民币和 2.01 亿元人民币，均录得显著增长。</p>
</div><p>Market analysis indicates that the subsidiaries' Q1 results reflect an overall improving trend, underscoring Fosun's clear growth trajectory following risk clearance in 2025. Fosun's fundamentals across pharmaceuticals and healthcare, insurance and finance, and cultural tourism remain solid, while steady recovery in the consumer segment is expected to further sustain growth momentum.</p>
<div class="lb-trans"><p>市场分析表明，子公司的第一季度业绩反映出整体改善的趋势，突显复星在 2025 年风险清除后的明确增长轨迹。复星在制药和医疗、保险和金融以及文化旅游等领域的基本面依然稳固，而消费板块的稳步复苏预计将进一步支撑增长动能。</p>
</div><p>Innovative drugs show robust growth momentum, unlocking potential for rapid growth</p>
<div class="lb-trans"><p>创新药物展现出强劲的增长动能，释放快速增长的潜力。</p>
</div><p>'We have always been committed to pharmaceutical innovation. By continuously strengthening our innovation pipeline, we are accelerating the clinical translation and commercialization of innovative technologies and products. We currently have multiple blockbuster candidates in the pipeline,' said Guo Guangchang. In his 2026 Letter to Shareholders, he repeatedly emphasized the Group's strategic focus on innovative drugs.</p>
<div class="lb-trans"><p>“我们始终致力于药物创新。通过不断加强我们的创新管道，我们正在加速创新技术和产品的临床转化和商业化。目前我们有多个重磅候选药物在管道中，” 郭广昌表示。在他 2026 年致股东信中，他多次强调集团对创新药物的战略关注。</p>
</div><p>Entering 2026, commercialization of Fosun's innovative drugs is accelerating. On 28 April, Fosun Pharma announced its Q1 2026 results. During the reporting period, the new drug application (NDA) for 4 innovative drugs were accepted, and 14 clinical trial applications for innovative drugs (calculated by approval) were approved by domestic and overseas regulatory authorities. Among them, denosumab injection (HLX14) secured approval in Canada, the NDA for bevacizumab injection (HLX04) was accepted in the United States, and the NDA for foritinib succinate capsules, methoxyetomidate hydrochloride injection, and one additional indication for FUMAINING were accepted by the National Medical Products Administration (NMPA).</p>
<div class="lb-trans"><p>进入 2026 年，复星的创新药物商业化正在加速。4 月 28 日，复星医药公布了 2026 年第一季度业绩。在报告期内，4 个创新药物的新药申请（NDA）获得受理，14 个创新药物的临床试验申请（按批准计算）获得国内外监管机构的批准。其中，地诺单抗注射液（HLX14）在加拿大获得批准，贝伐单抗注射液（HLX04）的 NDA 在美国获得受理，福美宁的 NDA、甲氧基乙酰胺盐酸注射液及一个额外适应症的申请获得国家药品监督管理局（NMPA）受理。</p>
</div><p>Overall, these results continue the robust growth momentum of innovative drug recorded in 2025. Results show that in 2025, Fosun Pharma had 16 indications of its 7 innovative drugs approved for marketing in China and overseas markets, while marketing applications for 6 innovative drug candidates were accepted. Revenue from innovative drugs reached RMB9.893 billion, representing a year-on-year increase of 29.59%, bringing the proportion of total pharmaceutical business revenue to 33.16%. As of the end of 2025, nearly 40 innovative drug clinical trials were approved by regulatory authorities in China, the United States and Europe, while multiple core products entered key clinical phases, laying a solid pipeline foundation for future commercial growth.</p>
<div class="lb-trans"><p>总体而言，这些结果延续了 2025 年创新药物的强劲增长动能。结果显示，2025 年复星医药的 7 个创新药物的 16 个适应症在中国和海外市场获得批准上市，同时 6 个创新药物候选药物的市场申请获得受理。创新药物的收入达到 98.93 亿元人民币，同比增长 29.59%，使得总制药业务收入的比例达到 33.16%。截至 2025 年底，近 40 个创新药物的临床试验获得中国、美国和欧洲监管机构的批准，同时多个核心产品进入关键临床阶段，为未来的商业增长奠定了坚实的管道基础。</p>
</div><p>As a benchmark enterprise for Fosun's innovative drugs, Henlius has achieved rapid progress in innovative drug research and development (R&amp;D) and commercialization since early 2026. In terms of R&amp;D, HANSIZHUANG and HLX07 have both achieved breakthrough advances, and multiple potential 'firstinclass' drugs are accelerating into clinical validation stages. Regarding global commercialization, Henlius entered into an exclusive commercialization and co-exclusive development and manufacturing license agreement with Eisai Co., Ltd. for HANSIZHUANG in Japan, with an aggregate potential consideration exceeding USD300 million. Meanwhile a subsidiary of Henlius obtained a Type I Marketing Authorization Holder (MAH) License for Pharmaceuticals from Tokyo Metropolitan Government, laying a solid foundation for further expansion into major Asian and global pharmaceutical markets.</p>
<div class="lb-trans"><p>作为复星创新药物的标杆企业，恒瑞自 2026 年初以来在创新药物研发和商业化方面取得了快速进展。在研发方面，汉斯珠昂和 HLX07 均取得了突破性进展，多个潜在的 “首创药物” 正在加速进入临床验证阶段。在全球商业化方面，恒瑞与 Eisai Co., Ltd.签署了汉斯珠昂在日本的独家商业化和共同开发及生产许可协议，潜在总对价超过 3 亿美元。同时，恒瑞的一家子公司获得了东京地方政府颁发的药品类型 I 市场授权持有者（MAH）许可证，为进一步拓展主要亚洲和全球制药市场奠定了坚实基础。</p>
</div><p>Fosun's innovative pipeline has entered a phase of frequent approvals and accelerated commercialization. R&amp;D investment and market returns are reinforcing each other in a virtuous cycle, providing strong support for sustained earnings growth and enhancing global competitiveness.</p>
<div class="lb-trans"><p>复星的创新管道已进入频繁批准和加速商业化的阶段。研发投资和市场回报相互强化，形成良性循环，为持续的盈利增长提供了强有力的支持，提升了全球竞争力。</p>
</div><p>Fosun subsidiaries across segments post solid results, reinforcing RMB10 billion profit target</p>
<div class="lb-trans"><p>复星各板块子公司发布稳健业绩，巩固 100 亿元人民币的利润目标。</p>
</div><p>The growth momentum of innovative drugs signals Fosun's improved performance. Meanwhile, Yuyuan, which was previously affected by impairments on real estate projects, has successfully navigated through the industry adjustment period, strengthening Fosun's weakest segment.</p>
<div class="lb-trans"><p>创新药物的增长动能标志着复星业绩的改善。同时，曾因房地产项目减值而受到影响的豫园，成功度过了行业调整期，增强了复星最薄弱的板块。</p>
</div><p>In Q1 2026, Yuyuan recorded net profit attributable to shareholders of the parent of RMB157 million, representing a year-on-year increase of 203%. Although the Q1 net profit remains modest, the strong growth momentum marks a positive turning point in Yuyuan's operating fundamentals, with subsequent earnings recovery expected to further unfold.</p>
<div class="lb-trans"><p>在 2026 年第一季度，豫园实现归属于母公司股东的净利润为 1.57 亿元人民币，同比增长 203%。尽管第一季度的净利润仍然较为温和，但强劲的增长势头标志着豫园经营基本面的积极转折，后续的盈利恢复预计将进一步展开。</p>
</div><p>Shede Spirits, another subsidiary in Fosun's consumer segment, has also successfully returned to a growth trajectory. In Q1 2026, it achieved operating revenue of RMB1.481 billion, representing a quarteronquarter increase of 106.45%. Meanwhile, its net profit reached RMB232 million, surpassing the net profit of RMB223 million for the full year of 2025.</p>
<div class="lb-trans"><p>复星消费板块的另一家子公司舍得酒业也成功回归增长轨道。在 2026 年第一季度，其营业收入达到 14.81 亿元人民币，环比增长 106.45%。与此同时，其净利润达到 2.32 亿元人民币，超过了 2025 年全年净利润 2.23 亿元人民币。</p>
</div><p>It is worth noting that Hainan Mining in the Intelligent Manufacturing segment delivered remarkable results. Driven by rising downstream demand for energy storage and power batteries, Hainan Mining achieved operating revenue of RMB1.193 billion and a net profit attributable to shareholders of the parent of RMB201 million in Q1 2026, representing a yearonyear increase of 25.13% and a significant quarter-on-quarter increase of 69%. The integrated lithium resource value chain operated steadily, contributing RMB99 million in net profit attributable to shareholders of the parent in Q1 and emerging as a core earnings growth driver. Additionally, the oil and gas business achieved stable production with improved efficiency. During the reporting period, the attributable oil and gas output amounted to 3.1865 million barrel equivalents, representing a year-on-year increase of 15.78%.</p>
<div class="lb-trans"><p>值得注意的是，智能制造板块的海南矿业交出了显著的业绩。受益于下游对储能和动力电池需求的上升，海南矿业在 2026 年第一季度实现营业收入为 11.93 亿元人民币，归属于母公司股东的净利润为 2.01 亿元人民币，同比增长 25.13%，环比大幅增长 69%。综合锂资源价值链稳定运营，为第一季度贡献了 9900 万元人民币的归母净利润，成为核心盈利增长驱动力。此外，油气业务实现了稳定的生产和效率提升。在报告期内，归属的油气产量达到 318.65 万桶当量，同比增长 15.78%。</p>
</div><p>Profit growth at subsidiaries across multiple segments is accelerating, strengthening market confidence in the certainty of Fosun's future earnings momentum.</p>
<div class="lb-trans"><p>多个板块子公司的利润增长正在加速，增强了市场对复星未来盈利动能确定性的信心。</p>
</div><p>Previously, Fosun's management team clearly set out its mediumterm financial roadmap at the 2025 annual results presentation: aiming to gradually restore a profit to the RMB10 billion level, targeting RMB60 billion in cash returns at the group level, bringing grouplevel total debt down to under RMB60 billion, and striving to achieve an 'investmentgrade' rating.</p>
<div class="lb-trans"><p>此前，复星管理团队在 2025 年年度业绩发布会上明确提出了中期财务路线图：旨在逐步恢复利润至 100 亿元人民币水平，目标是集团层面现金回报达到 600 亿元人民币，将集团总债务降至 600 亿元人民币以下，并力争实现 “投资级” 评级。</p>
</div><p>To illustrate its plan to achieve the 'RMB10 billion profit' target, Fosun's management team explained the '8424' restructuring framework. The '8' corresponds to RMB8 billion in profit from the four core subsidiaries'Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group; the first '4' reflects RMB4 billion in profit from secondtier subsidiaries such as Hainan Mining and Peak Reinsurance; the '2' represents approximately RMB2 billion in profit from investmentoriented enterprises; and the final '4' refers to a cap of RMB4 billion on grouplevel costs, including financing expenses. After these 'additions and subtractions', the Group aims to restore a profit level of RMB10 billion.</p>
<div class="lb-trans"><p>为了说明其实现 “100 亿元利润” 目标的计划，复星管理团队解释了 “8424” 重组框架。“8” 对应于四家核心子公司——复星医药、豫园、复星保险葡萄牙和复星旅游集团的 80 亿元人民币利润；第一个 “4” 反映来自海南矿业和峰再保险等二级子公司的 40 亿元人民币利润；“2” 代表来自投资导向企业的约 20 亿元人民币利润；最后的 “4” 指的是集团层面成本的上限为 40 亿元人民币，包括融资费用。在这些 “加减法” 之后，集团旨在恢复 100 亿元人民币的利润水平。</p>
</div><p>Fosun's Q1 results across business segments not only met market expectations following its 'repair the roof on a sunny day' efforts, but also reinforced confidence in restoring the RMB10 billion profit level. Analysts note that continued innovative drug commercialization, rapid growth in insurance, and stabilization in cultural tourism and consumer businesses position Fosun to further unlock growth momentum. Investors are advised to closely monitor full-year earnings growth and valuation recovery.</p>
<div class="lb-trans"><p>复星在各业务板块的第一季度业绩不仅符合市场预期，得益于其 “阳光天修屋顶” 的努力，还增强了恢复 100 亿元利润水平的信心。分析师指出，持续的创新药物商业化、保险业务的快速增长以及文化旅游和消费业务的稳定，使复星能够进一步释放增长动能。建议投资者密切关注全年盈利增长和估值恢复。</p>
</div><p>Backed by confidence in its long-term prospects, Fosun is actively repurchasing shares. Between 30 March, the date of the 2025 annual results announcement, and 27 April, Fosun International cumulatively repurchased 25.41 million shares. According to company announcements, the share buyback program is expected to continue.</p>
<div class="lb-trans"><p>在对长期前景充满信心的支持下，复星正在积极回购股份。从 2025 年年度业绩公告的日期 3 月 30 日到 4 月 27 日，复星国际累计回购 2541 万股。根据公司公告，股份回购计划预计将继续进行。</p>
</div><p>Recently, leading domestic and international securities firms such as Citi, UBS, Guotai Haitong, and China Securities have published research reports expressing optimism about Fosun's outlook. Citi highlighted that, based on the improving fundamentals, Fosun International is expected to deliver strong results in 2026.</p>
<div class="lb-trans"><p>最近，花旗、瑞银、国泰君安和中国证券等国内外领先证券公司发布了研究报告，对复星的前景表示乐观。花旗指出，基于基本面的改善，复星国际预计将在 2026 年交出强劲的业绩。</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 © 2026 ACN Newswire。保留所有权利。</p>
</div>

Fosun Subsidiaries Post Solid Q1, Core Businesses Fuel Growth

Asian Corporate Newswire

复星子公司公布了稳健的第一季度业绩，核心业务推动了增长